159 related articles for article (PubMed ID: 19624535)
1. Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer.
Luo HL; Fang FM; Chuang YC; Chiang PH
BJU Int; 2009 Dec; 104(11):1620-3. PubMed ID: 19624535
[TBL] [Abstract][Full Text] [Related]
2. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
Kollmeier MA; Stock RG; Cesaretti J; Stone NN
J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
[TBL] [Abstract][Full Text] [Related]
3. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
4. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
5. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection.
Peddada AV; Jennings SB; Faricy PO; Walsh RA; White GA; Monroe AT
J Urol; 2007 Nov; 178(5):1963-7. PubMed ID: 17868718
[TBL] [Abstract][Full Text] [Related]
6. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
[TBL] [Abstract][Full Text] [Related]
7. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
[TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
10. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
11. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
[TBL] [Abstract][Full Text] [Related]
12. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
13. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
[TBL] [Abstract][Full Text] [Related]
14. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
[TBL] [Abstract][Full Text] [Related]
15. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
16. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
17. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
[TBL] [Abstract][Full Text] [Related]
18. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.
Bachand F; Martin AG; Beaulieu L; Harel F; Vigneault E
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):679-84. PubMed ID: 18963537
[TBL] [Abstract][Full Text] [Related]
19. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan.
Chen YC; Chuang CK; Hsieh ML; Chen WC; Fan KH; Yeh CY; Lee CC; Hong JH
Urology; 2007 Jul; 70(1):101-5. PubMed ID: 17656217
[TBL] [Abstract][Full Text] [Related]
20. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
